»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Mastinib CAS 790299-79-5 Masivet Masitinib Ab 1010 manufacturer

5th

Gold Index: 88813

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Mastinib CAS 790299-79-5 Masivet Masitinib Ab 1010

Mastinib CAS 790299-79-5 Masivet Masitinib Ab 1010 

Payment Terms: T/T,L/C,WU 
Place of Origin: Sichuan, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C28H30N6OS
Production Capacity: 20 Kilogram/Year
Delivery Date: Within 7 days
CAS: 790299-79-5
Molecular Weight: 498.64
Specification: CP/USP/EP
Density: 1.281g/cm3
Alias: Masivet
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Brand: MOSINTER
Molecular Formula: C28H30N6OS
Content: 98%
Melting Point: 90-95°C
Storage condition: Refrigerator

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs.

Mastinib ( CAS: 790299-79-5)



Item

Index

Molecular Formula

C28H30N6OS

Molecular Weight

498.64

Specification

CP/USP/EP

Content

98%



Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In theUSAit is distributed under the name Kinavet and has been available for veterinaries since 2011.

Masitinib is being studied for several human conditions including cancers. It is used in Europe to fight orphan diseases.


Mechanism of action

Masitinib inhibits the receptor tyrosine kinase c-Kit which is displayed by various types of tumour. It also inhibits the platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).


Detailed description

Masitinib is a competitive inhibitor against ATP at concentrations ≤500 nM. Masitinib also potently inhibits recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, Masitinib demonstrates weak inhibition of Abl and c-Fms. Masitinib more strongly inhibits degranulation, cytokine production, and bone marrow mast cell migration than imatinib. In Ba/F3 cells expressing human wild-type Kit, Masitinib inhibits SCF (stem cell factor)-induced cell proliferation with an IC50 of 150 nM, while the IC50 for inhibition of IL-3-stimulated proliferation is at approximately >10 μM. In Ba/F3 cells expressing PDGFRα, Masitinib inhibits PDGF-BB-stimulated proliferation and PDGFRα tyrosine phosphorylation with IC50 of 300 nM. Masitinib also causes inhibition of SCF-stimulated tyrosine phosphorylation of human Kit in mastocytoma cell-lines and BMMC. Masitinib inhibits Kit gain-of-function mutants, including V559D mutant and Δ27 mouse mutant with IC50 of 3 and 5 nM in Ba/F3 cells. Masitinib inhibits the cell proliferation of mastocytoma cell lines including HMC-1α155 and FMA3 with IC50 of 10 and 30 nM, respectively.Masitinib inhibits cell growth and PDGFR phosphorylation in two novel ISS cell lines, which suggest that Masitinib displays activity against both primary and metastatic ISS cell line and may aid in the clinical management of ISS.


bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: